A recent study has identified STRN1-ALK (anaplastic lymphoma kinase) gene fusion as a novel marker in thyroid cancer, with the fused genes showing a higher prevalence in tumours exhibiting increased aggressiveness [124]. This evidence concerns the gene ALK and thyroid gland carcinoma.